✦ LIBER ✦

Occult malignancy in patients with venous thromboembolism: risk indicators and a diagnostic screening strategy

✍ Scribed by Oktar, G L; Ergul, E G; Kiziltepe, U

Book ID: 121658051
Publisher: Royal Society of Medicine Press
Year: 2007
Tongue: English
Weight: 100 KB
Volume: 22
Category: Article
ISSN: 0268-3555
DOI: 10.1258/026835507780346114

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Screening for occult malignancy with 18-

Screening for occult malignancy with 18-F-FDG-PET/CT in patients with unprovoked venous thromboembolism

✍ A. Alfonso; M. Redondo; T. Rubio; B. Del Olmo; P. Rodríguez-Wilhelmi; S. Varea; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 70 KB

Screening for occult cancer in patients

Screening for occult cancer in patients with acute venous thromboembolism

✍ M. MONREAL 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB

A pilot study utilizing whole body 18 F-

A pilot study utilizing whole body 18 F-FDG-PET/CT as a comprehensive screening strategy for occult malignancy in patients with unprovoked venous thromboembolism

✍ Matthew T. Rondina; Nathan Wanner; Robert C. Pendleton; Larry W. Kraiss; Russell 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 346 KB

Systematic screening for occult cancer i

Systematic screening for occult cancer in elderly patients with venous thromboembolism: a prospective study

✍ V. Rieu; S. Chanier; P. Philippe; M. Ruivard 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 117 KB

Has time come for screening for occult c

Has time come for screening for occult cancer in patients with venous thromboembolism?

✍ H. R. Büller 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB

ABO blood group is a potent risk factor

ABO blood group is a potent risk factor for venous thromboembolism in patients with malignant gliomas

✍ Michael B. Streiff; Jodi Segal; Stuart A. Grossman; Thomas S. Kickler; Edward G. 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 201 KB 👁 1 views

## Abstract ## BACKGROUND Venous thromboembolism (VTE) is a common cause of morbidity and mortality among patients with malignant gliomas. To investigate the pathogenesis of VTE and facilitate targeted prophylaxis strategies, the authors aimed to characterize VTE risk factors in these patients. #